Pentagastrin
A gastrin mimic used to provoke acid and calcitonin for testing
Pentagastrin is a synthetic five-amino-acid analogue of gastrin. Approved in the US as Peptavlon in 1974 and now discontinued, it was used to measure stomach acid output and, by provoking calcitonin release, to detect medullary thyroid carcinoma and C-cell hyperplasia.
Used in human trials: 0.5 µg/kg, Single bolus, Intravenous (Study: calcitonin stimulation test) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Pentagastrin mimics the active end of the hormone gastrin. For decades it was a standard diagnostic agent: given by injection, it stimulates the stomach to secrete acid, which let doctors measure maximal acid output, and it was used as a pharmacological stimulus in studies of acid-suppressing drugs. Infused side by side with histamine, the older stimulant, it drove the same maximal acid and pepsin output in a 1970 study, more potently and faster.
Its second use was in thyroid cancer screening. Medullary thyroid carcinoma arises from calcitonin-producing C cells, and a pentagastrin injection provokes a calcitonin surge that can unmask small tumours. In a 1978 family study, seven people showed a rise only after pentagastrin, and some were later found at surgery to have focal carcinoma or C-cell hyperplasia; a later study proposed a stimulated calcitonin cut-off of 275 ng/l to separate carcinoma from hyperplasia.
Head-to-head studies changed practice. Intravenous calcium raised calcitonin more than pentagastrin and was better tolerated overall, while pentagastrin failed to provoke any rise in a sizeable share of healthy adults, particularly women; side effects differed by sex. Even with the test, cancers can be missed: one RET carrier had normal stimulated calcitonin despite several small tumours. Surgeons also used it during operations to look for spread to neck nodes.
Its limits became clear: in families with MEN 2A, 15.4% of non-carriers had false-positive pentagastrin tests, and genetic RET testing is now the first-line screen. In the US the product is discontinued. Psychiatric researchers also used it as a challenge agent, because acting on cholecystokinin-B receptors in the brain it can provoke panic-like reactions.
In acid research it remained a workhorse long after its clinical heyday, used to test drugs such as netazepide and proton pump inhibitors. In psychiatry, doses as low as 0.2 µg/kg provoke panic-like anxiety within minutes, with ACTH and cortisol rising and little habituation on repeat. People with panic disorder are more sensitive: in one double-blind study 12 of 22 patient challenges ended in panic against 1 of 22 in healthy controls. Propranolol blocks the racing heart but not the fear, and in that study symptoms, hormones and heart rate did not move together; three days of ethinyl estradiol in men blunted only the heart-rate rise. In anaesthetised dogs it roughly tripled blood flow to the stomach and pancreas without changing blood pressure.
Mechanism of Action
Pentagastrin is a synthetic peptide carrying the active C-terminal sequence of gastrin; it acts on gastrin/CCK2 receptors.
Calcitonin release
Provokes calcitonin release from thyroid C cells, unmasking medullary thyroid carcinoma.
CCK2 receptors in the brain
Acting on CCK-B receptors, low doses provoke panic-like anxiety and ACTH and cortisol release.
Published Research
Studies of pentagastrin, from their PubMed abstracts.
Calcium vs pentagastrin for medullary carcinoma
In 39 people from affected families, seven showed a calcitonin rise only after pentagastrin injection, and some of these were found at operation to have focal medullary carcinoma and C-cell hyperplasia.
Separating carcinoma from hyperplasia
A pentagastrin-stimulated calcitonin peak of 275 ng/l distinguished medullary thyroid carcinoma from C-cell hyperplasia with 100% sensitivity and 89% specificity before surgery.
False positives in MEN 2A families
Among non-carriers in three MEN 2A families, 6.6% had false-positive basal calcitonin and 15.4% false-positive pentagastrin tests; the authors concluded RET gene analysis must be the first-line screen.
As a stimulus in acid studies
Pentagastrin-stimulated acid secretion was used to test intravenous pantoprazole, which suppressed acid output by more than 90% for up to 21 hours at 80 and 120 mg.
A research tool for provoking panic
In a double-blind challenge, pentagastrin, described as a synthetic analogue of cholecystokinin tetrapeptide acting on CCK-B receptors, produced panic-like reactions in 6 of 7 people with obsessive-compulsive disorder and 2 of 7 controls, a difference that did not reach significance.
Calcitonin cut-offs before thyroid surgery
In patients with thyroid nodules, a pentagastrin-stimulated calcitonin peak above 285 pg/mL separated medullary thyroid cancer from nodular goitre with 100% specificity and 82% sensitivity; peaks of 117 to 274 pg/mL pointed to C-cell hyperplasia.
Calcium is the stronger stimulus
In healthy adults given pentagastrin 0.5 µg/kg or calcium 2.5 mg/kg intravenously, calcium raised calcitonin far more and was better tolerated; pentagastrin produced no rise at all in 4 of 25 men and 12 of 25 women.
Calcium and pentagastrin tests compared
Calcitonin responses to the two stimuli correlated closely, and sex-specific cut-offs for basal and stimulated calcitonin best separated medullary carcinoma from C-cell hyperplasia.
Side effects of the two tests
Women had fewer side effects with pentagastrin than with calcium, while men had more nausea and abdominal cramps with pentagastrin.
A test that missed a cancer
In a family with a RET mutation, one carrier had normal basal and pentagastrin-stimulated calcitonin despite multifocal medullary microcancer.
During surgery
In 30 patients operated on for medullary thyroid cancer, a calcitonin rise after intraoperative pentagastrin flagged lateral neck node involvement in 8 of 10, missing two single micrometastases.
A stimulus for testing drugs
With pentagastrin infused at 0.6 µg/kg an hour to drive acid output, the gastrin/CCK2 antagonist netazepide inhibited the response in a dose-dependent way and 100 mg abolished it.
Anxiety at tiny doses
In healthy volunteers given intravenous boluses of 0.003 to 0.2 µg/kg, the highest dose provoked transient panic-like anxiety within two minutes along with a rise in C-peptide.
Repeat challenges
Given twice to 12 volunteers, pentagastrin produced robust anxiety, ACTH and cortisol responses both times, with only slight habituation.
More panic in panic disorder
In a double-blind study of 15 patients with panic disorder and 15 healthy controls given intravenous pentagastrin (0.1, 0.3 or 0.6 µg/kg) or saline, 12 of 22 patient challenges (55%) ended in a panic attack against 1 of 22 (5%) in controls; none followed saline, and panic rates did not differ between the three doses.
Propranolol blocks the racing heart, not the fear
In 16 healthy adults randomised to propranolol or placebo before pentagastrin, propranolol blocked the rise in heart rate but did not reduce panic or anxiety symptoms, and delayed and perhaps enhanced the cortisol response; symptom, cardiovascular and hormone responses did not move together, suggesting separate pathways.
Estrogen pretreatment in men
In a double-blind crossover study in 20 men (11 with panic disorder), three days of ethinyl estradiol (50 µg a day) did not reduce panic symptoms after a 30 µg intravenous pentagastrin bolus or change blood pressure responses, but blunted the rise in heart rate.
Matched histamine, and acted faster
In six healthy subjects given graded intravenous infusions, histamine and pentagastrin produced equal maximal acid and pepsin output; pentagastrin was more potent and acted faster, while the composition of the gastric juice was the same with both.
Gut blood flow in dogs
In anaesthetised dogs, intravenous pentagastrin raised splanchnic blood flow in a dose-dependent, inverted-U pattern, to about three to three and a half times baseline in the gastric and pancreatico-duodenal beds at 2-4 µg/kg, without changing heart rate, cardiac output or arterial pressure.
Dosing Data
There is no current US product. The calcitonin test used 0.5 µg/kg as an intravenous bolus; acid studies used continuous infusions such as 0.6 µg/kg an hour.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Pentagastrin is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Pentagastrin is prepared and given by clinical staff, in a hospital or specialist clinic, as a test.
In the carded studies it was injected into a vein as a stimulation test, with blood calcitonin measured before thyroid surgery.
Source: PMID 20039894 and PMID 679097 (studies carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Pentagastrin is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous (Single bolus; Study: calcitonin stimulation test).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Study: calcitonin stimulation test: Samples at 2, 5 and 15 minutes; Study: stimulated gastric acid secretion: During the measurement.
When effects appear: unknown; no source on this page gives a time to effect for Pentagastrin. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: False-positive calcitonin results in non-carriers. Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Pentagastrin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the studies above”).
Interactions
Unknown: a PubMed search for human interaction studies of Pentagastrin (reviewed 2026-10-05) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Pentagastrin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Approved in the US as Peptavlon, NDA 017048, on July 26, 1974). Sport: Unsettled (S0 may apply).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
No current US label: the product is discontinued and DailyMed has no label (read October 3, 2026).
Legal Status
Pentagastrin is no longer marketed in the US. DailyMed lists only a 2012 compounded pentagastrin solution, not an approved label.
Frequently Asked Questions
?What was pentagastrin used for?
As a diagnostic injection: to measure stomach acid secretion and to provoke calcitonin release when screening for medullary thyroid carcinoma.
?Is pentagastrin still available?
Not in the US, where Peptavlon is listed as discontinued. Genetic RET testing has replaced it as the first-line screen in affected families.
?How reliable was the pentagastrin test?
It could unmask small tumours, but in one family study 15.4% of people without the mutation had false-positive results.
?Why was pentagastrin used in psychiatry research?
It acts on cholecystokinin-B receptors and can trigger panic-like attacks, so researchers used it under controlled conditions to study panic and anxiety disorders. In one study it provoked panic-like reactions in 6 of 7 people with obsessive-compulsive disorder.
?What replaced it for thyroid cancer testing?
Genetic RET testing for families at risk, and intravenous calcium as the calcitonin stimulus. In healthy adults calcium raised calcitonin far more and was better tolerated, and pentagastrin failed to produce any rise in about half the women tested.
?Was it used during thyroid surgery?
Yes, experimentally. In 30 patients operated on for medullary thyroid cancer, a calcitonin rise after an intraoperative pentagastrin injection flagged lateral neck node spread in 8 of 10 who had it; two single micrometastases were missed.
References
- [fda] US FDA, Drugs@FDA (openFDA): PEPTAVLON, NDA 017048 (July 26, 1974), marketing status discontinued; no label on DailyMed. Read October 3, 2026.
- [pubmed] Verdy M, et al. "Calcium infusion and pentagastrin injection in diagnosis of medullary thyroid carcinoma." Can Med Assoc J, 1978;119(1):29-35. PMID: 679097.
- [pubmed] Milone F, et al. "Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels." Clin Endocrinol (Oxf), 2010;73(1):85-8. PMID: 20039894.
- [pubmed] Hernández G, et al. "False-positive results of basal and pentagastrin-stimulated calcitonin in non-gene carriers of multiple endocrine neoplasia type 2A." Thyroid, 1997;7(1):51-4. PMID: 9086571.
- [pubmed] Pisegna JR, et al. "Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study." Am J Gastroenterol, 1999;94(10):2874-80. PMID: 10520836.
- [pubmed] de Leeuw AS, et al. "Pentagastrin has panic-inducing properties in obsessive compulsive disorder." Psychopharmacology (Berl), 1996;126(4):339-44. PMID: 8878350.
- [pubmed] Kartal Baykan E, et al. "Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer." Turk J Med Sci, 2021;51(2):650-656. PMID: 33128357.
- [pubmed] Doyle P, et al. "Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults." J Clin Endocrinol Metab, 2009;94(8):2970-4. PMID: 19491231.
- [pubmed] Colombo C, et al. "Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer." J Clin Endocrinol Metab, 2012;97(3):905-13. PMID: 22170709.
- [pubmed] Ubl P, et al. "Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences." Endocrine, 2014;46(3):549-53. PMID: 24272596.
- [pubmed] Pirich C, et al. "Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer." Wien Klin Wochenschr, 2012;124(19-20):723-4. PMID: 22965292.
- [pubmed] Scheuba C, et al. "The value of intraoperative pentagastrin testing in medullary thyroid cancer." Surgery, 2007;141(2):166-71; discussion 171-2. PMID: 17263971.
- [pubmed] Boyce M, et al. "Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects." Br J Clin Pharmacol, 2013;76(5):689-98. PMID: 23432534.
- [pubmed] Radu D, et al. "Anxiogenic effects of the CCK(B) agonist pentagastrin in humans and dose-dependent increase in plasma C-peptide levels." Psychopharmacology (Berl), 2002;161(4):396-403. PMID: 12073167.
- [pubmed] Khan S, et al. "Effect of repeat exposure on neuroendocrine and symptom responses to pentagastrin." Psychiatry Res, 2004;126(3):189-95. PMID: 15157745.
- [pubmed] van Megen HJ, et al. "Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients." Psychopharmacology (Berl), 1994;114(3):449-55. PMID: 7855203.
- [pubmed] Khan S, et al. "Effects of propranolol on symptom and endocrine responses to pentagastrin." Psychoneuroendocrinology, 2004;29(9):1163-71. PMID: 15219640.
- [pubmed] McManus K, et al. "Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin." J Affect Disord, 2001;66(2-3):273-9. PMID: 11578682.
- [pubmed] Aubrey DA, et al. "Effects of histamine acid phosphate and pentagastrin on gastric secretion in normal human subjects." Gut, 1970;11(5):395-404. PMID: 4913624.
- [pubmed] Hulstaert PF, et al. "Hemodynamic actions of pentagastrin." Scand J Gastroenterol, 1980;15(1):7-15. PMID: 7367825.
Sources & Citations
Studies were read from their PubMed abstracts. DailyMed lists only a 2012 pentagastrin solution from a compounding pharmacy, not an approved label. Read October 7, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.